ProPhase Labs, Inc. PRPH

What this company does

We are a growth oriented and diversified next generation biotech, genomics and consumer products company that develops and commercializes novel drugs, dietary supplements, and compounds, and human genomic testing. We offer whole genome sequencing and related services through our wholly-owned subsidiary, Nebula Genomics, Inc. (“Nebula”) and DNA Complete, Inc. ("DNA Complete"). Our wholly owned subsidiary, ProPhase BioPharma, Inc. (“PBIO”) is focused on the licensing, development and commercialization of novel drugs, dietary supplements, and compounds. We also develop and market dietary supplements under the TK Supplements® brand. We own the exclusive rights to the BE-Smart Esophageal Pre-Cancer diagnostics screening test and related intellectual property assets. Currently, we plan to commercialize the BE-Smart test as a Laboratory Developed Test (“LDT”).

Written from the business description in ProPhase Labs, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 1 June 2026. Every sentence was checked against that document before publication.